GSK Sues Pfizer for Lost Profits in RSV Vaccine Patent Clash (1)

GlaxoSmithKline Plc filed a lawsuit alleging Pfizer Inc.’s Abrysvo, a vaccine for respiratory syncytial virus in patients aged 60 and older, infringes four patents for GSK’s Arexvy, the first RSV vaccine approved in the US.

GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC, subsidiaries of the pharmaceutical giant, are seeking damages of lost profits and royalties for the alleged infringement, according to a complaint filed Wednesday in the US District Court for the District of Delaware.

GSK also wants a court order blocking Pfizer from selling Abrysvo for use in adults over 60, but it said it “is not seeking to ...